Researchers at Massachusetts General Hospital are now reporting that the tumor microenvironment itself can be therapeutically primed to facilitate accumulation of multiple clinically relevant therapeutic nanoparticles to tumors.
A new triple therapy approach using a checkpoint inhibitor and T-cell therapy is showing considerable promise in the treatment of Merkel cell carcinoma.
Atezolizumab was approved for treating patients with metastatic non–small-cell lung cancer who experienced disease progression during or following platinum-containing chemotherapy. Now, it turns out this agent may have a role in combating breast cancer.
A 43-year-old man presents with a nodule in the right upper chest wall area. After a biopsy is performed, what is your diagnosis?
A new study has found that high tumor mutation load is associated with older age, absence of oncogenic mutations, and presence of tumor suppressor gene mutations.
Vaccination with the immune complement component C3d protein blocks tumor-mediated immunosuppression, enhancing antitumor immune response.
Higher doses of the kinase inhibitor brigatinib as second-line therapy for ALK-positive non–small-cell lung cancer may be an option for some patients.
Researchers at Weill Cornell Medicine are reporting that they have successfully converted cells from blood vessels in mice into blood-forming stem cells.
A study may be able to identify which men with aggressive prostate cancer will benefit from androgen deprivation therapy.
We spoke with Monica Fradkin on ways to help minimize adverse events in patients receiving immunotherapy treatment at the Oncology Nursing Society 42nd Annual Congress, held May 4–7 in Denver.
We spoke with Victoria Miller, FNP-BC, on how to identify and treat cytokine release syndrome in cancer patients being treated with immunotherapy at the Oncology Nursing Society 42nd Annual Congress, held May 4–7 in Denver.
Researchers have now mapped genetic changes that help drive glioblastoma and are hoping this will lay the foundation for targeted treatment of the disease.
Researchers from Johns Hopkins University report on a cascade of events that appears to correlate with early cancer recurrence and decreased overall survival.
A new study is suggesting that intravenous and subcutaneous rituximab share similar efficacy and safety profiles.
A new study is suggesting there may be an association with high tumor levels of the protein PD-L1 and head and neck disease recurrence.